ASA "Extremely Troubled" About Removal of Sodium Thiopental From Market

Written by Rachel Fields | January 24, 2011 | Print  |

The American Society of Anesthesiologists says it is "extremely troubled" to learn that the anesthetic sodium thiopental, or Pentothal, has been removed from the U.S. market after its sole manufacturer ceased production of the drug, according to an ASA release.

According to the ASA, sodium thiopental is an "important and medically necessary anesthetic agent that has been used for years to induce anesthesia in patients undergoing surgical procedures." While the drug's use has dropped in recent years with the introduction of propofol and other medications, sodium thiopental is still extremely valuable, especially in cases involving geriatric, neurologic, cardiovascular and obstetric patients.

Read the ASA release on sodium thiopental.

Read more on anesthesia:

-ASA Clarifies Medically-Induced Coma Versus Sedation

-Facility Use of Blood Glucose Monitors Leads to Treatment Errors, Anesthesiologist Warns

-Study: Improved Ultrasound Imaging of Injected Anesthetics on the Horizon

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.